Thousand Oaks, California (ots/PRNewswire) – Amgen announced today that it has submitted a request to the European Medicines Agency (EMA) for a re-examination of the negative opinion issued in March by the Committee For Medicinal Products for Human Use (CHMP) for the use of Vectibix in combination with chemotherapy for patients with wild-type KRAS metastatic [...]
Tag Archive > Treatment Option
Treatment With Prolia(R) (denosumab) Associated With Significantly Greater Adherence, Compliance and Persistence Compared to Alendronate
Thousand Oaks, California (ots/PRNewswire) – Amgen today announced new data that showed postmenopausal women with osteoporosis had significantly greater adherence, compliance, and persistence during Prolia(R) (denosumab) treatment than during alendronate treatment, an oral bisphosphonate commonly used to treat osteoporosis. Adherence to treatment, which includes both compliance (a measure of how well patients follow directions for [...]
Amgen Statement on CHMP Opinion on Vectibix(R) (Panitumumab) Use With Chemotherapy in Metastatic Colorectal Cancer
Thousand Oaks, California (ots/PRNewswire) – Amgen today issued the following statement: Amgen has received notice that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion for Amgen’s application to extend the marketing authorization in Europe for Vectibix(R) (panitumumab) to include combination with chemotherapy for [...]
Eisai Opens for Business in the Netherlands
Hatfield, England (ots/PRNewswire) – Eisai Europe Limited, a subsidiary of Eisai Co., Ltd announces the establishment of its sales and marketing operation in its wholly owned subsidiary in the Netherlands based in Amsterdam. The first Eisai product on the Dutch market is the epilepsy treatment Zonegran (zonisamide). Commenting on the opening of the new subsidiary, [...]
Prolia(TM) (denosumab) Receives Best New Drug Honor at Scrip Awards
Thousand Oaks, California, November 5 (ots/PRNewswire) – Amgen is pleased to announce that it has won the Best New Drug award for Prolia(TM) (denosumab), a novel treatment approved in the United States (U.S.) for women with postmenopausal osteoporosis at high risk for fracture, at the 2010 Scrip Awards ceremony Nov. 4 in London. Named one [...]
Multaq(R) First-line Option in New 2010 ESC Guidelines for the Management of Atrial Fibrillation
Paris, August 29, 2010 (ots/PRNewswire) – Sanofi aventis announced today that the European Society of Cardiology (ESC) 2010 new Guidelines for the Management of Atrial Fibrillation (AF) have been released and recommend that Multaq(R) (dronedarone) should be used for maintenance of sinus rhythm as a first-line treatment option in all patients with paroxysmal and persistent [...]
Pitavastatin Demonstrates Sustained Efficacy, Tolerability and LDL-C Target Attainment Over 52 Weeks
Wokingham, England, April 28, 2010 (ots/PRNewswire) – New long-term phase III data published today in Atherosclerosis demonstrates that, of patients with primary hypercholesterolaemia or combined dyslipidaemia who received 4mg of pitavastatin, 74% and 73.5% achieved NCEP* and EAS* low-density lipoprotein cholesterol (LDL-C) targets at 52 weeks, respectively. At the end of this open-label one-year extension [...]
First Treatment to Improve Survival in 20 Years Now Available for Patients With Osteosarcoma (Bone Cancer)
Osaka, Japan and London (ots/PRNewswire) – Takeda Pharmaceutical Company Limited (“Takeda”) and Takeda Pharmaceuticals Europe Limited (“TPEU”), its wholly owned subsidiary for oversight of pan-European sales and marketing, jointly announced today that Mepact(R) (mifamurtide)(1), the first new treatment in 20 years to improve survival in patients with osteosarcoma (malignant bone cancer)(2), is now commercially available [...]
First Treatment to Improve Survival in 20 Years
Osaka, Japan and London (ots/PRNewswire) – Takeda Pharmaceutical Company Limited (“Takeda”) and Takeda Pharmaceuticals Europe Limited (“TPEU”), its wholly owned subsidiary for oversight of pan-European sales and marketing, jointly announced today that Mepact(R) (mifamurtide)(1), the first new treatment in 20 years to improve survival in patients with osteosarcoma (malignant bone cancer)(2), is now commercially available [...]
Pitavastatin is Non-Inferior to Atorvastatin and Simvastatin and Demonstrates Sustained Efficacy and Tolerability Over 52 Weeks
Barcelona, Spain (ots/PRNewswire) – – Pitavastatin Represents Long-Term Treatment Option for Patients With Primary Hypercholesterolaemia or Combined Dyslipidaemia New phase III data presented at the European Society of Cardiology congress (ESC) demonstrated that pitavastatin is non-inferior to atorvastatin and simvastatin at usual therapeutic doses in patients with primary hypercholesterolemia or combined dyslipidemia, as measured by [...]
Novel Chemotherapy Agent Bendamustine Significantly More Effective First-Line Therapy Than Chlorambucil in CLL
Cambridge, England (ots/PRNewswire) – – Blood Marrow Normalised in 31% (Versus 2%) of Patients, With Manageable Side-Effects Nearly a third (31%) of all bendamustine-treated patients saw all clinical evidence of their advanced chronic lymphocytic leukaemia (CLL) disappear when used as a first-line treatment option, according to the results of a large new multicentre phase III [...]
FDA Approves Multaq(R) for Patients With Atrial Fibrillation or Atrial Flutter
Paris (ots/PRNewswire) – – Multaq(R) Approved to Reduce the Risk of Cardiovascular Hospitalization in Patients With Atrial Fibrillation or Atrial Flutter – U.S Commercial Launch Planned for the Summer of 2009 Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the U.S. Food and Drug Administration (FDA) has approved Multaq(R) (dronedarone) 400 mg Tablets. Patients [...]
YM BioSciences’ Subsidiary Resolves Proposed Arbitration With Oncoscience AG
(pressebox) MISSISSAUGA, Canada, 29.06.2009, YM BioSciences Inc. (NYSE Amex:YMI, TSX:YM, AIM:YMBA), a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, today reported that YM’s subsidiary, CIMYM BioSciences Inc. and Oncoscience AG have resolved the issues between the companies in a cooperative effort. [...]
New NICE Guideline for Type 2 Diabetes Recognises Benefits From Newer Agents for Blood Glucose Control
London (ots/PRNewswire) – – For Healthcare and Pharmaceutical Correspondents Only – NICE Recommends Considering DPP-4 Inhibitors as a Second Line Treatment Option in Appropriate Patients Merck Sharp & Dohme Limited (MSD) welcomes the publication of the guideline for type 2 diabetes newer agents1 from the National Institute for Health and Clinical Excellence (NICE) in the [...]
Tolerx Expands Phase 3 ‘DEFEND’ Trial of Otelixizumab in Europe
Cambridge, Massachusetts (ots/PRNewswire) – Tolerx, Inc., today announced that DEFEND (Durable Response Therapy Evaluation For Early or New Onset Type 1 Diabetes), the Phase 3 trial of otelixizumab, an investigational novel targeted immunotherapeutic, has begun enrollment of new onset autoimmune type 1 diabetes patients in Europe. In DEFEND, preserving beta cell function subsequent to the [...]
